| Scientific Sessions |
| |
| Drug Delivery to the Posterior Segment |
Back To Section List |
| Chairperson: D. Tang Liu |
IIBMX biomarker for biocompatibility with rat retina rod cells
Ari Koskelainen, Finland |
Intravitreal delivery of Lucentis (Ranibizumab) and challenges in dose selection
Jacques Gaudreault, USA
|
Application of encapsulated cell technology for treating Ophthalmic diseases
Weng Tao, USA
|
Interaction of factors controlling neovascularization and vascular permeability in the eye
Stanley A. Vinores, USA
|
Bioerudivel sustained- release systems: changing concepts and paradigms in targeting eye diseases
Jose Cardillo, Brazil
|
Overcoming Challenges to Posterior Drug Delivery
Joan-En Lin, USA
|
| |
| Ocular Blood Flow in Eye Disease |
Back To Section List |
| Chairperson: A. Harris |
The importance of ocular blood flow in macular degeneration
Alon Harris, USA |
The effects of medication on ocular blood flow
Mark Lesk, Canada |
The importance of ocular blood flow in glaucoma
Peter Netland, USA |
| |
| Antioxidants |
Back To Section List |
| Chairpersons: P. Bernstein, A. Ohira |
Biochemistry and biophysics of oxidants and anti-oxidants in age-related macular degeneration: new insights into an old age disease
Paul Bernstein, USA |
Measurements of Macular Carotenoid Pigments by Resonace Raman Spectroscopy in Japanese
Akihiro Ohira, Japan |
Antioxidant
proerties of zeaxanthin – role of singlet oxygen quenching
and free radical scavenging
Tadeusz Sarna, Poland |
Shedding light on the role of RPE lipofusin in macular degeneration
Janet Sparrow, USA |
| |
Ocular Angiogenesis Inhibition -
Pre-clinical
Studies |
Back To Section List |
| Chairperson: A. Das |
Introduction
Arup Das, USA |
Vascular reconstruction with autologous bone marrow cells for the treatment of retinal vascular diseases
Martin Friedlander, USA |
Somatostatin analogs in angiogenesis inhibition
Maria Grant, USA |
Inhibition of ocular angiogenesis by modulation of the Ephrin B2/Ephrin B4 pathway
David Hinton, USA |
Targeting prostaglandins both upstream and downstream of VEGF receptor activation
John Penn, USA |
| |
| Ocular Toxicology |
Back To Section List |
| Chairperson: F. Fraunfelder |
The latest data from the National Registry of drug induced ocular side effects
Rick Fraunfelder, USA |
Ocular function testing in multicentre trials: How to meet this challenge?
Eberhart Zrenner, Germany |
What are the preferred ocular tests for human ocular toxicology?
Wiley Chambers, USA |
| |
In Vitro Approaches to Ocular Diseases
& Drug
Discovery |
Back To Section List |
| Chairperson: N. Agarwal |
Differentiated RGC-5 cells and drug development
Neeraj Agarwal, USA |
The roles of CamKinase in cell death and survival of the retinal ganglion cell
Nigel Cooper, USA |
Cell based assays - from screens to genes: role in drug discovery
Ganesh Prasanna, USA |
Aquaporin water channels: A promising target for drug development
Raj Kumar Patil, USA |
Optic nerve astrocytes, a model for cell signaling and drug targets for glaucoma
Thomas Yorio, USA |
| |
| The Philosophy of Drug Development |
Back To Section List |
| Chairperson: R. Vogel |
Introduction: The issues for the patient,
the physician, the regulators and the pharmaceutical industry
Roger Vogel, USA |
Quantification of visual function and
visual change-instruments and measures
Maria Verdugo, USA |
Value based medicine-the new paradigm
Melissa Brown |
The requirement for efficacy in assessment
of drugs for sight threatening diseases
Wiley Chambers, USA |
Who decides the availability of care?
Julia Bottomley |
Treatment of retinal disorders: Challenges for the small company
Gary Novack, USA
|
| |
| European Drug Development |
Back To Section List |
| Chairperson: J.G. Cunha-Vaz |
The European Vision Institute and the network of clinical trial centers of ophthalmology
Jose Cunha-Vaz, Portugal |
The issue of preservative efficacy testing requirements in the development of ophthalmic drugs in Europe
Klaus Geldsetzer, Germany |
New regulations for clinical studies in Europe
Yves Geysels, Belgium |
The role of the CROs in the Ophthalmological drug development in Europe
P.P. Elena, France |
| |
| Imaging Technologies as End Points |
Back To Section List |
| Chairperson: S. Krupsky |
Discussion: Anatomic versus functional end points
Wiley Chambers, USA
Marc de Smet, Netherlands
Ran Zeimer, USA |
| |
